IN8BIO, Inc.
INAB4.170USD
+0.567+15.74%
Close 06/06, 16:00（ET）Quotes delayed by 15 min
338.85MMarket Cap
LossP/E TTM
More Details of IN8bio Inc Company
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Company Info
Company codeINAB
Company nameIN8bio Inc
IPO dateNov 12, 2020
Founded at2018
CEOMr. William T. Ho
Number of employees18
Security typeOrdinary Share
Fiscal year-endNov 12
AddressEmpire State Building
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10118
Phone16466006438
Websitehttps://www.in8bio.com
Company codeINAB
IPO dateNov 12, 2020
Founded at2018
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
26.23K
+26.32%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William T. Ho
Mr. William T. Ho
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Patrick Mccall, CPA
Mr. Patrick Mccall, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Lawrence S. Lamb, Ph.D.
Dr. Lawrence S. Lamb, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
--
--
Dr. Jeremy R. Graff, Ph.D.
Dr. Jeremy R. Graff, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
26.23K
+26.32%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, May 16
Update time: Fri, May 16
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Bios Equity Partners, LP.
8.32%
Franklin Advisers, Inc.
5.51%
Ho (William Tai Wei)
2.71%
Alyeska Investment Group, L.P.
2.01%
The Vanguard Group, Inc.
1.74%
Other
79.69%
Shareholder Statistics
Shareholder
Proportion
Bios Equity Partners, LP.
8.32%
Franklin Advisers, Inc.
5.51%
Ho (William Tai Wei)
2.71%
Alyeska Investment Group, L.P.
2.01%
The Vanguard Group, Inc.
1.74%
Other
79.69%
Type
Shareholder
Proportion
Venture Capital
8.39%
Investment Advisor/Hedge Fund
8.31%
Individual Investor
4.30%
Hedge Fund
2.09%
Investment Advisor
1.09%
Private Equity
1.09%
Research Firm
0.02%
Other
74.72%
Institutional Shareholding
Update time: Mon, Mar 3
Update time: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
64
36.86M
46.48%
+9.17M
2024Q4
64
40.67M
56.11%
+11.42M
2024Q3
66
26.31M
53.00%
+3.73M
2024Q2
66
26.43M
54.24%
+1.59M
2024Q1
62
24.15M
55.92%
+314.96K
2023Q4
58
23.08M
53.43%
+4.41M
2023Q3
55
17.49M
62.06%
+5.54M
2023Q2
52
17.21M
67.21%
+7.01M
2023Q1
46
16.24M
65.08%
+6.18M
2022Q4
45
8.68M
40.92%
-6.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bios Equity Partners, LP.
8.60M
10.58%
--
--
Dec 31, 2024
Franklin Advisers, Inc.
5.70M
7.01%
+5.70M
--
Dec 31, 2024
Ho (William Tai Wei)
2.80M
3.45%
--
--
Feb 16, 2025
Alyeska Investment Group, L.P.
5.06M
6.23%
+4.63M
+1.06K%
Dec 31, 2024
The Vanguard Group, Inc.
1.42M
1.75%
--
--
Dec 31, 2024
AIGH Capital Management, LLC.
4.64M
5.71%
-2.10M
-31.09%
Dec 31, 2024
Brandt (Peter C)
622.89K
0.77%
--
--
Feb 16, 2025
Sigma Planning Corporation
1.04M
1.28%
+190.10K
+22.33%
Dec 31, 2024
Geode Capital Management, L.L.C.
515.19K
0.63%
+185.92K
+56.46%
Dec 31, 2024
Roemer (Alan S.)
299.87K
0.37%
--
--
Feb 16, 2025
View more
Related ETFs
Update time: Fri, Jun 6
Update time: Fri, Jun 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
